Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 17 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Leveraging MCO Success to Elevate Portfolio Clubs to the International Stage
Brera Holdings (NASDAQ: BREA), an Ireland-based company focused on expanding a global portfolio of men’s…
-
QualityStocksNewsBreaks – Why Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is ‘One to Watch’
Silvercorp Metals (NYSE American: SVM) (TSX: SVM) is a Canadian mining company with a strong track…
-
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology,…